Jiangsu HengRui Medicine Co., Ltd. $600276.SS
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS72
PHASE 3 / 2-331
RECRUITING42
READOUTS ≤12 MONTHS28
READOUT SLIPPED >6 MO30%
Delay Index: of 46 active trials registered more than a year ago, 14 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open Jiangsu HengRui Medicine Co., Ltd. on the live radar map → 📅 $600276.SS readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| SHR-1316、Paclitaxel (Albumin Bound)、Carboplatin NCT04316364 |
P3 | Recruiting | Non-Small-Cell Lung Cancer | 537 | 2023-04-15 |
| Hetrombopag NCT05864014 |
P3 | Active, not recruiting | Chemotherapy-Induced Thrombocytopenia | 213 | 2025-03-03 |
| HRS-9231 NCT06731829 |
P2 | Not yet recruiting | For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) Lesions | 78 | 2025-04 |
| camrelizumab; famitinib malate NCT04906993 |
P3 | Active, not recruiting | Cervical Cancer | 443 | 2025-06-10 (+29 mo) |
| Linperlisib ; Rituximab NCT06981988 |
P1/2 | Not yet recruiting | Relapsed/Refractory Indolent NHL | 80 | 2025-08 |
| HRS-1167 tablets NCT06689163 |
P1/2 | Recruiting | Prostate Cancer | 66 | 2025-11-30 |
| HRS-4642 NCT06385678 |
P1/2 | Active, not recruiting | Advanced KRAS G12D Mutant Solid Tumors | 47 | 2025-12 (+2 mo) |
| HR070803 plus oxaliplatin, 5-FU/LV, bevacizumab NCT05945901 |
P2/3 | Active, not recruiting | Colorectal Cancer | 669 | 2025-12-01 |
| HRS-6213 NCT07070349 |
P1/2 | Recruiting | Patients With Solid Tumors | 48 | 2026-01 |
| SHR-3167 NCT07018453 |
P2 | Active, not recruiting | Type 2 Diabetes Mellitus | 173 | 2026-02 (+2 mo) |
| SHR-A1811 Injection NCT07051486 |
P2 | Recruiting | Recurrent or Metastatic Cervical Cancer | 60 | 2026-02 |
| SHR-A1811 NCT06430437 |
P3 | Recruiting | Non-Small Cell Lung Cancer With HER2- Mutations | 300 | 2026-02 |
| RSS0393 Ointment NCT07102888 |
P2 | Not yet recruiting | Plaque Psoriasis in Children; Plaque Psoriasis in Adolescents | 20 | 2026-02 |
| RSS0393 ointment NCT06918743 |
P2 | Not yet recruiting | Psoriatic Subjects | 147 | 2026-03 |
| SHR0302Base gel NCT06790862 |
P2 | Active, not recruiting | Vitiligo | 155 | 2026-03-03 |
| SHR-A1811 NCT05814354 |
P3 | Active, not recruiting | Breast Cancer | 551 | 2026-03-20 (+14 mo) |
| HRS-6768 NCT06925581 |
P1/2 | Recruiting | Advanced Solid Tumors | 84 | 2026-04 |
| camrelizumab NCT04342910 |
P3 | Recruiting | Gastric Cancer | 550 | 2026-04-01 (+48 mo) |
| SHR2554; Chidamide analog tablets NCT06122389 |
P3 | Recruiting | Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy | 130 | 2026-05 |
| SHR-A1904 NCT05277168 |
P1/2 | Recruiting | Advanced Solid Tumors | 83 | 2026-05 (+2 mo) |
| SHR-A1811 Injection NCT06057610 |
P3 | Active, not recruiting | HER2-PositiveRecurrent or Metastatic Breast Cancer | 868 | 2026-07-15 (-15 mo) |
| TACE+Camrelizumab+Apatinib mesylate NCT05320692 |
P3 | Active, not recruiting | Hepatocellular Carcinoma | 423 | 2026-07-30 (+24 mo) |
| Camrelizumab NCT04639180 |
P3 | Active, not recruiting | Hepatocellular Carcinoma (HCC) | 687 | 2026-07-31 (+24 mo) |
| HRS-1738 Injection NCT07056439 |
P1/2 | Not yet recruiting | PET Imaging in Patients With Prostate Cancer | 50 | 2026-08 |
| SHR6390 NCT04842617 |
P3 | Active, not recruiting | Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage,Female Breast Cancer | 5274 | 2026-10-31 |
| SHR-A1811 combined with Pyrotinib. NCT06015048 |
P1/2 | Recruiting | HER2-expressing Advanced Solid Tumors | 364 | 2026-11 |
| Bupivacaine Liposome Injection NCT06529432 |
P2 | Recruiting | Local Analgesia Via Nerve Block | 96 | 2026-11 (+1 mo) |
| SHR-A1811 & Pyrotinib/SHR-A1811 & SHR-1316 NCT05482568 |
P1/2 | Recruiting | Advanced Non-small Cell Lung Cancer | 324 | 2026-12 (+36 mo) |
| HRS-6209 Capsules NCT06974929 |
P1/2 | Recruiting | Breast Cancer | 80 | 2026-12 (+12 mo) |
| Lutetium (177Lu) Oxodotreotide Injection;long-acting Octreotide NCT05884255 |
P3 | Recruiting | Advanced Gastroenteropancreatic Neuroendocrine Tumor | 220 | 2026-12 |
| HRS-5041 tablets NCT06568094 |
P1/2 | Recruiting | Prostate Cancer | 100 | 2026-12 (+15 mo) |
| SHR-3167 Injection NCT07472725 |
P2 | Active, not recruiting | Diabetes Mellitus, Type 2 | 102 | 2026-12 |
| NCT04957550 NCT04957550 |
P3 | Active, not recruiting | Psoriatic Arthritis | 418 | 2026-12-13 (+37 mo) |
| HRS-9190 NCT07746726 |
P3 | Recruiting | Neuromuscular Blockade | 320 | 2026-12-31 |
| SHR-A1811 NCT05424835 |
P3 | Active, not recruiting | HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane | 381 | 2026-12-31 (+24 mo) |
| SHR-A1811 NCT06413745 |
P2 | Active, not recruiting | HER2 Expression / Amplification in Patients With Biliary Tract Cancer | 59 | 2026-12-31 (+16 mo) |
| Fuzuloparib , Abiraterone acetate and Prednisone NCT04691804 |
P3 | Active, not recruiting | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | 496 | 2026-12-31 |
| FH-006 for Injection NCT07136142 |
P1/2 | Recruiting | Malignant Solid Tumor | 150 | 2027-02 |
| SHR0302 Tablets NCT07251595 |
P2 | Recruiting | Non-segmental Vitiligo | 176 | 2027-03 |
| HRS-4642 NCT06520488 |
P1/2 | Recruiting | Advanced Solid Tumors | 118 | 2027-03 |
| Rezvilutamide Tablets NCT07241416 |
P3 | Recruiting | Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | 206 | 2027-03 |
| SHR2554 NCT06368167 |
P2 | Not yet recruiting | Follicular Lymphoma | 105 | 2027-04 |
| SHR-A1811 NCT06828354 |
P3 | Recruiting | Ovarian Cancer | 300 | 2027-05 |
| Pyrotinib NCT03980054 |
P3 | Active, not recruiting | Breast Cancer | 2135 | 2027-06 (+58 mo) |
| SHR-9803 NCT06906731 |
P1/2 | Not yet recruiting | Advanced Solid Tumors | 27 | 2027-06 |
| SHR-A1811 NCT06123494 |
P3 | Recruiting | HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma | 360 | 2027-06-30 |
| SHR4640 ;Febuxostat NCT07362355 |
P2 | Recruiting | Primary Gout and Hyperuricemia | 340 | 2027-07 |
| HRS-4508 tablet NCT07003321 |
P2 | Recruiting | Solid Tumor | 120 | 2027-09 |
| SHR-3167 Injection NCT07920939 |
P3 | Not yet recruiting | Type 2 Diabetes | 450 | 2027-10 |
| HRS-4508+ Capecitabine NCT07140393 |
P1/2 | Recruiting | Solid Tumor | 120 | 2027-10 |
| RSS0343 Tabella NCT06775340 |
P2 | Recruiting | Adolescent Asthma | 252 | 2027-11 (+24 mo) |
| SHR-4394 NCT07407283 |
P1/2 | Recruiting | Prostate Cancer | 100 | 2027-11 |
| FH-006 ; SHR-1316 ; BP102 ; Cisplatin ; Carboplatin NCT07241767 |
P2 | Recruiting | Lung Cancer | 200 | 2027-11 |
| FH-006 NCT06735144 |
P1/2 | Recruiting | Malignant Solid Tumor | 200 | 2027-12 |
| SHR-A1811 for Injection NCT07196774 |
P3 | Active, not recruiting | Early-stage or Locally Advanced HER2-positive Breast Cancer | 740 | 2027-12 |
| HRS-4357 injection NCT07311694 |
P3 | Recruiting | PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer | 370 | 2027-12 |
| HRS-6209 in Combination with Fulvestrant NCT06555068 |
P1/2 | Recruiting | Advanced Unresectable or Metastatic Breast Cancer; Advanced Solid Tumors | 528 | 2027-12 (+24 mo) |
| HRS-4508 tablet NCT07232849 |
P2 | Recruiting | Lung Cancer | 100 | 2027-12 |
| SHR2554 Tablets NCT07102901 |
P2 | Recruiting | Advanced Gastric Cancer; Metastatic Gastric Cancer | 351 | 2027-12 |
| SHR-3167 NCT07913061 |
P3 | Not yet recruiting | Diabetes Mellitus, Type 2 | 680 | 2028-01 |
| HORIZON-CRC221 NCT07796763 |
P2 | Not yet recruiting | Advanced Colorectal Cancer Expressing HER2 | 48 | 2028-05-01 |
| Trastuzumab Rezetecan for Injection NCT07497386 |
P2 | Recruiting | Unresectable Locally Recurrent Breast Cancer; Unresectable Locally Metastatic Breast Cancer | 150 | 2028-06 |
| SHR2554; SHR-A2102 NCT07175220 |
P2 | Recruiting | Locally Advanced or Metastatic Non-small Cell Lung Cancer | 200 | 2028-10 |
| Irinotecan Hydrochloride Liposome Injection (II); Oxaliplatin; 5Fluorouracil; Calcium folinate NCT07238283 |
P3 | Recruiting | First-line Treatment of Metastatic Pancreatic Cancer | 662 | 2028-10 |
| HRS-8364 Tablet NCT07446153 |
P1/2 | Recruiting | Solid Tumor | 282 | 2028-12 |
| Hetrombopag Olamine NCT07286032 |
P3 | Recruiting | Patients With Chemotherapy-Induced Thrombocytopenia | 150 | 2028-12 |
| HS-20093 for Injection NCT07230106 |
P2 | Recruiting | Prostate Cancer | 218 | 2028-12 |
| HRS-7172 + AG + SHR-1316 NCT07806058 |
P1/2 | Recruiting | Pancreatic Cancer | 140 | 2028-12-31 |
| HRS-4642 + AG NCT07232875 |
P3 | Recruiting | KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting | 588 | 2029-04 |
| FH-006 NCT07790380 |
P3 | Recruiting | Locally Advanced, Recurrent or Metastatic ESCC Patients Who Have Failed Prior PD-1/PD-L1 Inhibitors Combined With Platinum-based Chemotherapy | 480 | 2029-06-30 |
| SHR-A1811 NCT06126640 |
P3 | Active, not recruiting | HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy | 1615 | 2030-04 |
| HRS-6209 + Letrozole NCT07894328 |
P3 | Not yet recruiting | Breast Cancer | 1050 | 2031-07-30 |